First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
Clinically Significant Outcomes of Interest in the Comparative Effectiveness Review (3 of 3)
A variety of validated assessment instruments are used to measure outcomes of treatment of bipolar disorder with antipsychotics. For assessing mania, the Clinician Administered Rating Scale for Mania was often used, as well as the Young Mania Rating Scale (YMRS). Depression was evaluated with the Calgary Depression Scale for Schizophrenia (CDS-S), the Hamilton Depression Scale (HAM-D), and the Montgomery-Asberg Depression Rating Scale (MADRS). Positive and negative symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS). The effect of bipolar disorder and treatment with antipsychotics on sleep was evaluated by assessing the number of awakenings, sleep efficiency, minutes in the rapid eye movement (REM) stage, total REM activity, and total sleep time. Global ratings and total scores were reported using the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impressions–Bipolar Scale (CGI-BP), the Clinical Global Impressions–Improvement Subscale (CGI-I), and the PANSS.
- Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Review No. 63 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC054-EF. Available at www.effectivehealthcare.ahrq.gov/antipsychotics-adult.cfm.
Your slide tray is being processed.